Breaking News

Ori Biotech Delivers IRO Platform for CGT Manufacturing to Customers

Designed to increase throughput, decrease COGS, and reduce batch failures.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Oribiotech Ltd., a provider of cell and gene therapy (CGT) manufacturing technology, announces the first customer deliveries of the new IRO platform, specifically designed to help address the current challenges in CGT manufacturing. In December 2024, four IRO instruments were delivered to multiple contract development and manufacturing organizations (CDMOs) and a global pharmaceutical company. Through its Lightspeed Early Access Program which generates data with partners, IRO has proven to au...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters